Spasticity - Pipeline Review, H2 2014

Date: October 30, 2014
Pages: 74
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S2B6F6154B9EN
Leaflet:

Download PDF Leaflet

Spasticity - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Spasticity - Pipeline Review, H2 2014’, provides an overview of the Spasticity’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Spasticity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Spasticity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Spasticity Overview
Therapeutics Development
Pipeline Products for Spasticity - Overview
Pipeline Products for Spasticity - Comparative Analysis
Spasticity - Therapeutics under Development by Companies
Spasticity - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Spasticity - Products under Development by Companies
Spasticity - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Canbex Therapeutics Ltd.
Concert Pharmaceuticals, Inc.
Echo Pharmaceuticals B.V.
Escape Therapeutics, Inc.
GW Pharmaceuticals plc
Merz Pharma GmbH & Co. KgaA
Novartis AG
Osmotica Pharmaceutical Corp.
Raptor Pharmaceuticals Corp.
SciFluor Life Sciences, LLC
Spasticity - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADX-71441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbaclofen ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTP-354 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nabiximols - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-426 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selurampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Spasticity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tezampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VSN-16R - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spasticity - Recent Pipeline Updates
Spasticity - Dormant Projects
Spasticity - Discontinued Products
Spasticity - Product Development Milestones
Featured News & Press Releases
Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity
Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS
Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis
Jul 11, 2013: Echo Pharmaceuticals Announces Phase 2 Results for Namisol, Its' Pipeline Product for Oral Administration of ?9-Tetrahydrocannabinol and Appoints The Sage Group
Jun 10, 2013: Concert Pharma Initiates Phase I Clinical Trial Of CTP-354 For Treatment Of Spasticity And Pain
May 07, 2013: GW Pharma Announces Sativex Commercialization Approval In Italy
Apr 10, 2013: GW Pharma's Sativex Moved To Schedule 4 Of UK Drugs Act
Mar 19, 2013: GW Pharma Provides Update On Pricing Negotiations For Sativex In Germany
Dec 10, 2012: Osmotica Pharma Initiates Phase III Studies With Arbaclofen ER Tablets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Spasticity, H2 2014
Number of Products under Development for Spasticity - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Spasticity - Pipeline by Addex Therapeutics Ltd, H2 2014
Spasticity - Pipeline by Canbex Therapeutics Ltd., H2 2014
Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H2 2014
Spasticity - Pipeline by Echo Pharmaceuticals B.V., H2 2014
Spasticity - Pipeline by Escape Therapeutics, Inc., H2 2014
Spasticity - Pipeline by GW Pharmaceuticals plc, H2 2014
Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014
Spasticity - Pipeline by Novartis AG, H2 2014
Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H2 2014
Spasticity - Pipeline by Raptor Pharmaceuticals Corp., H2 2014
Spasticity - Pipeline by SciFluor Life Sciences, LLC, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Spasticity Therapeutics - Recent Pipeline Updates, H2 2014
Spasticity - Dormant Projects, H2 2014
Spasticity - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Spasticity, H2 2014
Number of Products under Development for Spasticity - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Addex Therapeutics Ltd
Canbex Therapeutics Ltd.
Concert Pharmaceuticals, Inc.
Echo Pharmaceuticals B.V.
Escape Therapeutics, Inc.
GW Pharmaceuticals plc
Merz Pharma GmbH & Co. KgaA
Novartis AG
Osmotica Pharmaceutical Corp.
Raptor Pharmaceuticals Corp.
SciFluor Life Sciences, LLC
Skip to top


Spasticity - Pipeline Review, H1 2015 US$ 1,600.00 May, 2015 · 85 pages
Muscle Spasticity - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 49 pages
Muscle Spasticity - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 51 pages
Spasticity - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Spasticity - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: